Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Microsoft’s new AI system BioEmu will help decode protein motion and help in faster discovery of drugs, said CEO Satya ...

Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...

Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...

Centella AI streamlines drug discovery using AI-powered platforms, reducing R&D time and cost with real-world scientific validation ...

Drug discovery startup Synfini Inc. said today it has closed on an $8.9 million expansion funding round led by JSL Health ...

Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.

Every protein in the body is encased in a water shell that directs protein structure, provides vital stability and steers ...

A woman paroled last fall after serving time on a multi-count drug conviction has been arrested on numerous felony counts ...